Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICN Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (842)	5/5/1998 3:51:00 PM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 1029

i'm not in and have just begun following icn, however, i thought this news might be worthy of a post (a few para's snipped): Stock Investor Trading News Initiates Coverage of ICN Pharmaceuticals May 5, 1998 10:01 AM AUSTIN, Texas, May 5 /PRNewswire/ -- Stock Investor Trading News initiates coverage of ICN Pharmaceuticals ICN with a "Strong Buy" rating and a price target of $84 per share. "ICN remains undervalued in light of the FDA's antiviral drug advisory panel's recommendation of approval for ICN's antiviral drug Rebetol for treatment of Hepatitis C, and strong secular growth in the company' Eastern European operations. In our opinion ICN is one of the best values in the drug sector," says David Barney, Analyst for SITN. . . . David Barney, Technical Analyst for Stock Investor Trading News, notes that "the stock has been in a consolidation pattern over the last few weeks as investors waited for the FDA to review Rebetol. Now that the stock has broken out of a triple top formation and closed at a new high, I think the stock could make a strong move higher over the next few weeks." "The stock is clearly under accumulation as investors search for value in this volatile market. The drug sector represents somewhat of a safe haven in the minds of many investors looking for an alternative to technology stocks. With the worries over Asia and inflation still on investors minds, we feel that ICN offers a very unique opportunity for investors to participate in a rapidly growing company which still offers value," notes Mr. Barney. investor.msn.com